© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
BeyondSpring Inc. (BYSI) stock surged +21.97%, trading at $0.77 on NASDAQ, up from the previous close of $0.63. The stock opened at $0.61, fluctuating between $0.61 and $0.79 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 10, 2026 | 0.61 | 0.79 | 0.61 | 0.77 | 800.26K |
| Sep 09, 2026 | 0.62 | 0.63 | 0.61 | 0.63 | 39.83K |
| Sep 08, 2026 | 0.62 | 0.63 | 0.60 | 0.62 | 31K |
| Sep 04, 2026 | 0.63 | 0.65 | 0.60 | 0.62 | 26.77K |
| Sep 03, 2026 | 0.64 | 0.65 | 0.62 | 0.62 | 42.99K |
| Sep 02, 2026 | 0.60 | 0.65 | 0.60 | 0.61 | 40.13K |
| Sep 01, 2026 | 0.61 | 0.65 | 0.60 | 0.60 | 52.65K |
| Aug 31, 2026 | 0.64 | 0.66 | 0.61 | 0.62 | 55.84K |
| Aug 28, 2026 | 0.61 | 0.67 | 0.61 | 0.67 | 113.57K |
| Aug 27, 2026 | 0.68 | 0.70 | 0.57 | 0.64 | 289.57K |
| Aug 26, 2026 | 0.70 | 0.72 | 0.69 | 0.69 | 35.17K |
| Aug 25, 2026 | 0.71 | 0.77 | 0.71 | 0.72 | 44.39K |
| Aug 24, 2026 | 0.70 | 0.72 | 0.70 | 0.71 | 26.88K |
| Aug 21, 2026 | 0.72 | 0.75 | 0.70 | 0.72 | 59.15K |
| Aug 20, 2026 | 0.70 | 0.76 | 0.70 | 0.72 | 33.24K |
| Aug 19, 2026 | 0.72 | 0.79 | 0.70 | 0.72 | 154.26K |
| Aug 18, 2026 | 0.72 | 0.74 | 0.67 | 0.72 | 141.88K |
| Aug 17, 2026 | 0.84 | 0.84 | 0.70 | 0.71 | 322.81K |
| Aug 14, 2026 | 0.87 | 0.88 | 0.78 | 0.84 | 777.18K |
| Aug 13, 2026 | 0.76 | 1.35 | 0.76 | 1.00 | 38.82M |
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focused on developing novel cancer treatments. Its flagship product is Plinabulin, a selective immune-modulating and microtubule-binding agent. Plinabulin has successfully advanced through Phase III clinical trials for two distinct applications: the prevention of chemotherapy-induced neutropenia, and the treatment of advanced non-small cell lung cancer. The company is also exploring Plinabulin's efficacy in combination with various immuno-oncology drugs; specifically, alongside nivolumab (a PD-1 antibody) for NSCLC, and with nivolumab and ipilimumab (a CTLA-4 antibody) for small cell lung cancer (SCLC). Furthermore, it is being investigated in conjunction with PD-1 or PD-L1 antibodies and radiation to address a range of cancers. Beyond its lead asset, BeyondSpring's pipeline includes three preclinical-stage small molecule immune agents and a proprietary drug development platform. The company, founded in 2010, maintains its headquarters in New York, New York.
| Employees | 44 |
| Beta | 0.42 |
| Sales or Revenue | $1.35M |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |